Loading
NASDAQHealthcareBiotechnology
Latest quote
$4.20
−$0.17 · -3.89%
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
Previous close
$4.20
−$0.17 · -3.89%
Pre-market
$4.18
−$0.02 · -0.48%
Oct 9, 5:31 AM ET
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
71
Undervalued
Sentiment
64
Bullish
Risk
56
Elevated Risk
Momentum
56
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
Day range
Current $4.20
52-week range
Current $4.20
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2M USD | — | 1.34M USD | 2.7M USD | 2.7M USD |
| Cost of goods sold | 1.99M USD | — | — | — | — |
| Gross profit | 13K USD | — | 1.34M USD | 2.7M USD | 2.7M USD |
| Research and development | 6.38M USD | 6.32M USD | 8.97M USD | 27.64M USD | 20.99M USD |
| Selling, general, and administrative | 8.72M USD | 6.46M USD | 8.14M USD | 15.66M USD | 5.94M USD |
| Operating expenses | 15.1M USD | 12.78M USD | 17.11M USD | 43.3M USD | 26.93M USD |
| Interest income | 2.37M USD | 4.98M USD | 8.03M USD | 3.57M USD | 347K USD |
| Interest expense | — | 853K USD | 3.58M USD | — | — |
| Depreciation and amortization | 121K USD | 193K USD | 196K USD | 58K USD | 77K USD |
| Operating income | −15.09M USD | −12.78M USD | −15.77M USD | −40.6M USD | −24.22M USD |
| Net income | 64.05M USD | −19.06M USD | 5.53M USD | −37.76M USD | −22.24M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jan 16, 2026 | $0.25Special | Jan 16, 2026 | Jan 26, 2026 |
Ex-dividend Jan 16, 2026
$0.25
Special
Record Jan 16, 2026 · Payment Jan 26, 2026
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM3.74M0.00%77.7B USD0.19%$277.57-0.05%
Vanguard Russell 2000 ETFVTWO986.17K0.01%18B USD0.06%$112.1-0.10%
iShares Micro-Cap ETFIWC476.23K0.04%1.32B USD0.60%$182.79-0.31%
Dimensional - US Small Cap ETFDFAS267.07K0.00%33.66B USD0.31%$78.10+0.23%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC263.12K0.03%1.04B USD0.20%$85.92+0.21%
Dimensional - US Core Equity 2 ETFDFAC261.7K0.00%88.28B USD0.21%$45.11-0.15%
Avantis U.S. Small Cap Equity ETFAVSC243.07K0.01%3.04B USD0.25%$69.96+0.47%
Vanguard Russell 2000 Value ETFVTWV158.47K0.01%1.4B USD0.06%$186.06+0.59%iShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCDimensional - US Core Equity 2 ETFDFACAvantis U.S. Small Cap Equity ETFAVSCVanguard Russell 2000 Value ETFVTWVAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
